Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

UCB Fellowship logo

Therapeutic areas

Primary interest: Particularly in areas of Epilepsy, Inflammation, Neuroinflammation, Immunomodulation, Fibrosis, Metabolic disease, and Bone/ Cartilage diseases

Secondary Interest: Adjacencies to our current therapy areas of immunology and neurology.

For neurology only: approaches to electrical intervention and stem cells.

Rational and therapeutic modulation of the microbiome in severe disease.

Novel targets, therapeutic modalities, translational assays and clinical capabilities to support immuno-oncology.

Right target

Projects with a robust testable translational hypothesis.

Integrative biology approaches to link multiscalar datasets of human biology to provide further confidence in novel potential drug targets

Projects with data from human systems linking function of target with disease pathophysiology, where therapeutic intervention will effect a significant benefit for patients.

Ability to determine the functional consequence of gene mutation in humans in complex biological systems, including in animal models (rodent, zebrafish, drosophila).

Of particular interest are secreted or cell surface proteins as targets for biologic-based therapeutics, including translatable models suitable for high throughput screening of bi-specific antibodies.

Protein expertise looking at identification of conformers with different biological function.

Right therapeutic molecule

Enabling chemical and biological technologies for discovery of therapeutics against currently intractable molecular targets.

Functional cellular assays where there is a strong link to human disease pathophysiology.

Imaging technologies and capabilities to measure drug-target engagement in vivo.

Right indication

Experimental medicine studies in small well-characterised cohorts of patients with robust biomarkers or clinical endpoints.

Integrated approaches to demonstrate dysfunctional targets and pathways in different disease indications

Novel biomarker identification approaches


Right patient

Robust, sensitive, specific and clinically practical approaches to patient stratification

Integrating clinical, imaging and molecular information to identify patient sub-populations

Remote monitoring technologies to allow real world monitoring of efficacy and safety of therapeutic intervention.